The effect of sildenafil in cystic fibrosis disease

Not Applicable

• Conditions: Cystic fibrosis.; Mucoviscidosis

• Registration Number: IRCT2016040920175N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Confirmed CF with respiratory; gastrointestinal or urogenital symptom with positive test for CF in two times; (CL>60) male and female more than 8 years with potency of doing spirometry; stable vital sign without upper or lower respiratory tract infection; FEV1>50%.
Exclusion criteria: History of sensitivity to sildenafil or daily usage of systemic corticostroid or ibuprofen; LFT>3*normal; biliary cirhosis; portal hypertention; heart diseases such as aortic stenosis, arrhythmia, coronary artery disaeaes; neurological or hematologic or renal disaeas; takingof alfa blocker or nitrate or calcium blocker or CYP3A4 inhibitor such as ketoconazole or erythromycin; history of migraine; druge sensitivity or side effect or no patient inclination to continuation.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FEV1/FVC. Timepoint: Before the study and 3months after the start. Method of measurement: Spirometry.;FEV1. Timepoint: Befor the study and 3 months after the stsrt. Method of measurement: Spirometry.;FEF25-75. Timepoint: Before the study and 3months after the start. Method of measurement: Spirometry.;Walking tolerance. Timepoint: Before the study and 3montha after the start. Method of measurement: Minute, ET test.

Secondary Outcome Measures

Name	Time	Method
Drug sensitivity. Timepoint: Weekly. Method of measurement: History.